UNC-Chapel Hill
Chapel Hill, North Carolina, 27759, United States
NCT Number: NCT00609531
The purpose of this proof of concept study is to use functional magnetic resonance imaging and behavioral assessments to investigate the effect of citalopram on restricted repetitive behaviors in people with autism spectrum disorders.
Looking for future studies?
Notify Me10 year–55 year
All sexes
Interventional
Phase 1
Chapel Hill, North Carolina, 27759, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Pill, 5-20mg once a day for twelve weeks
Other names: Celexa
Placebo pill once a day for twelve weeks
Time frame: two 2-hr scans
Time frame: Upon study completion
Time frame: Baseline, wks 2, 4, 8, endpoint
University of North Carolina, Chapel Hill
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01031407
Adult, Asperger Syndrome
Bethesda, Maryland, United States
View Trial DetailsNCT02628808
Autism Spectrum Disorder, Autism Spectrum Disorders
Bordeaux, France
View Trial DetailsNCT02586935
Autism Spectrum Disorder, Autism Spectrum Disorders
Hamilton, Ontario, Canada
View Trial DetailsNCT01250938
Autism Spectrum Disorder, Autism Spectrum Disorders
Tallahassee, Florida, United States
View Trial Details